CBER public affairs office
Executive Summary
FDA's Center for Biologic Evaluation and Research is establishing a new division, under the Office of Compliance, called the Division of Congressional and Public Affairs. Starting Dec. 5, the division will be headed by current chief of the Freedom of Information Office (under the Center for Drugs) Mark Elengold. The division, which will serve as a liaison to Congress and respond to requests for information about activities in Biologics, is expected to have a staff of 15 - seven from existing Fol positions in Biologics and eight new staffers. Fol staffer CarolAnn Wooton will move into Elengold's spot on an acting basis....